In bladder cancer previously resistant to immune checkpoint inhibition, the addition of a hypomethylating agent to anti-PD-L1 therapy led to some patients experiencing an immune response and prolonged stable disease, though responses were not seen indicating the need for more efficacious immunosensitization [39]. This evidence concerns the gene CD274 and urinary bladder carcinoma.